Entry Point Capital, LLC Relay Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 26,368 shares of RLAY stock, worth $126,566. This represents 0.11% of its overall portfolio holdings.
Number of Shares
26,368Holding current value
$126,566% of portfolio
0.11%Shares
2 transactions
Others Institutions Holding RLAY
# of Institutions
203Shares Held
156MCall Options Held
207KPut Options Held
40K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$134 Million1.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.5MShares$69.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$50.6 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY9.25MShares$44.4 Million5.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.38MShares$35.4 Million0.88% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $577M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...